|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Zanbilowicz, Adam, DPM MS |
|---|---|
| Information provided by: | Zanbilowicz, Adam, DPM MS |
| ClinicalTrials.gov Identifier: | NCT00533247 |
Purpose
This double blinded, placebo controlled, study seeks to determine the efficacy of preoperative anti-inflammatory therapy on the reduction of postoperative pain in knee arthroplasty surgery. Pre-emptive use of NSAIDS has demonstrated only modest reduction in post-operative pain in previous studies. However, the short duration of dosing in those studies did not capitalized on the anti-inflammatory properties of NSAIDS. Short-term use of NSAIDS only provides pain relief and does not address inflammation. Traditional NSAIDS cannot be used preoperatively due to platelet effects. Celecoxib, however, is both an analgesic and anti-inflammatory, but does not interfere with bleeding. It can therefore be safely used before surgery. This study hypothesizes that the use of celecoxib for seven days preoperatively reduces postoperative inflammation and consequently pain. A detailed Medline search has not identified any studies into the preoperative use of an NSAID at a dosing level that achieves anti-inflammatory effects.If effective in reducing postoperative pain, this research could lead to a new understanding of the role inflammation plays in orthopedic procedures and other elective procedures and thus improve patient outcomes in the future.
| Condition | Intervention |
|---|---|
|
Postoperative Pain |
Drug: Celecoxib |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Preemptive Anti-Inflammatory Use of Celecoxib in Knee Arthroplasty Surgery: a Double Blinded, Placebo-Controlled Study. |
| Estimated Enrollment: | 200 |
Show Detailed Description
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Subjects will be excluded from the study for the following reasons:
Contacts and Locations| Contact: Adam Zanbilowicz, BA DPM MS | 604-885-8803 | zanbilowicz@pol.net |
| Canada, British Columbia | |
| Vancouver, British Columbia, Canada | |
| Principal Investigator: | Adam Zanbilowicz, BA DPM MS | Vancouver Coastal Health Authority |
More Information
| Study ID Numbers: | PAC01 |
| Study First Received: | September 20, 2007 |
| Last Updated: | September 20, 2007 |
| ClinicalTrials.gov Identifier: | NCT00533247 History of Changes |
| Health Authority: | Canada: Health Canada; Canada: Ethics Approval by University of BC Office of Research Services |
|
Cox-2 Inhibitor Pre-emptive Pain Preoperative Pain |
Pain Prophylaxis Celebrex Celecoxib |
|
Anti-Inflammatory Agents Celecoxib Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Cyclooxygenase Inhibitors Pain Enzyme Inhibitors Pharmacologic Actions Signs and Symptoms Pathologic Processes |
Postoperative Complications Sensory System Agents Analgesics, Non-Narcotic Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Peripheral Nervous System Agents Analgesics Antirheumatic Agents Central Nervous System Agents Pain, Postoperative |